510(k) · Cleared
ClearedARCHITECT Toxo IgG
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Abbott Laboratories · LGD Enzyme Linked Immunoabsorbent Assay, Toxoplasma Gondii
Cleared on May 19, 2022 as substantially equivalent to K993319 (bioMerieux, Inc., 2000) after a 444-day review. Its family tree reaches back 1 generation to 2000.
- Decided
- May 19, 2022
- Review
- 444 days
- Class
- Class II
- Product code
- LGD
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K993319 (2000). No later device cites it as a predicate yet.
- Root · 1 generation backK993319 Vidas Toxo Igg II (TXG) Assay Model 30 210bioMerieux, Inc. · 2000
- This deviceK210596 ARCHITECT Toxo IgGAbbott Laboratories · 2022
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K993319 | Vidas Toxo Igg II (TXG) Assay Model 30 210 | bioMerieux, Inc. | 2000 | — |
| 0 (this device) | K210596 | ARCHITECT Toxo IgG | Abbott Laboratories | 2022 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LGD? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LGD device
- #1 K242022 Access Toxo IgGscore 9.7 · 3 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K993319 | Vidas Toxo Igg II (TXG) Assay Model 30 210Summary page 5…Name: Toxoplasma gondii serological reagents Governing Regulation: 21 CFR § 866.3780 Code: LGD Predicate Device: BioMérieux VIDAS TOXO IgG II (TXG) assay (k993319) ARCHITECT Toxo IgG 510(k) Page 5-2 Section… | 2000 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- 2 other devices also cite its predicate K993319.
How does its category compare?
All LGD devicesLGD Enzyme Linked Immunoabsorbent Assay, Toxoplasma Gondii: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.
FDA decisions per year · LGD
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LGD
Too few LGD 510(k)s in any year since 2007 to give a median.
Recalls per year · LGD
1in 2021
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LGD
89in 2025
MAUDE reports naming product code LGD, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 2 | 4 |
| 2008 | 2 | — | 1 | 14 |
| 2009 | 1 | — | 0 | 91 |
| 2010 | 0 | — | 1 | 71 |
| 2011 | 2 | — | 0 | 115 |
| 2012 | 0 | — | 0 | 75 |
| 2013 | 2 | — | 0 | 35 |
| 2014 | 0 | — | 0 | 22 |
| 2015 | 1 | — | 0 | 121 |
| 2016 | 0 | — | 0 | 140 |
| 2017 | 1 | — | 0 | 173 |
| 2018 | 0 | — | 0 | 100 |
| 2019 | 0 | — | 0 | 59 |
| 2020 | 0 | — | 0 | 87 |
| 2021 | 0 | — | 1 | 38 |
| 2022 | 1 | — | 0 | 73 |
| 2023 | 0 | — | 0 | 118 |
| 2024 | 2 | — | 0 | 81 |
| 2025 | 1 | — | 0 | 89 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The ARCHITECT Toxo IgG assay is a chemiluminescent microparticle immunoassay (CMIA) used for the quantitative determination of IgG antibodies to Toxoplasma gondii in human serum and plasma on the ARCHITECT i System.
The ARCHITECT Toxo IgG assay is to be used as an aid in the detection of immune status to Toxoplasma gondii in individuals, including women of child-bearing age, and as an aid in the diagnosis of Toxoplasma gondii infection.
Not intended for use in screening blood, plasma, or tissue donors.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K210596 · printed Nov 3, 2026
Cite this page
510(k) Report. “K210596: ARCHITECT Toxo IgG.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K210596
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026